SB
EVFM

Strategic Blueprint’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Strategic Blueprint’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7
Closed – – 1428
2021
Q2 		$0 Buy
+7
New +$133 ﹤0.01% 1451

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Strategic Blueprint's EVFM Position: Q3 2021 in Review

Strategic Blueprint sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 7 shares.

Strategic Blueprint first reported a position in EVFM in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

  • Strategic Blueprint reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Strategic Blueprint sold 7 Evofem Biosciences, Inc. Common Stock shares in Q3 2021.
  • Strategic Blueprint first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Strategic Blueprint's Evofem Biosciences, Inc. Common Stock position peaked at $0 in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.